Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non–small cell lung cancer

Toshiyuki Hirano, Hiroyuki Yasuda, Junko Hamamoto, Shigenari Nukaga, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Tatsuya Niimi, Shinya Mimasu, Hideki Sakagami, Kenzo Soejima, Tomoko Betsuyaku

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Multiple epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) have been developed to effectively inhibit EGFR-derived signals in non–small cell lung cancer (NSCLC). In this study, we assessed the efficacy of EGFR-TKIs, including a novel third-generation inhibitor naquotinib (ASP8273), in clinically relevant EGFR mutations, including L858R, exon 19 deletion, L858RþT790M, exon 19 deletionþT790M with or without a C797S mutation, and several exon 20 insertion mutations. Using structural analyses, we also elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in EGFR exon 20 insertion mutations. The efficacy of naquotinib in cells with L858R, exon 19 deletion and exon 19 deletionþT790M was comparable with that of osimertinib. Interestingly, naquotinib was more potent than osimertinib for L858RþT790M. Additionally, naquotinib and osimertinib had comparable efficacy and a wide therapeutic window for cells with EGFR exon 20 insertions. Structural modeling partly elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in two EGFR exon 20 insertion mutants, A767_V769dupASV and Y764_V765insHH. In summary, we have characterized the efficacy of EGFR-TKIs for NSCLC using in vitro and structural analyses and suggested the mechanism of activation and resistance to EGFR-TKIs of EGFR exon 20 insertion mutations. Our findings should guide the selection of appropriate EGFR-TKIs for the treatment of NSCLC with EGFR mutations and help clarify the biology of EGFR exon 20 insertion mutations.

Original languageEnglish
Pages (from-to)740-750
Number of pages11
JournalMolecular Cancer Therapeutics
Volume17
Issue number4
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Pharmacology
Exons
Insertional Mutagenesis
Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non–small cell lung cancer. / Hirano, Toshiyuki; Yasuda, Hiroyuki; Hamamoto, Junko; Nukaga, Shigenari; Masuzawa, Keita; Kawada, Ichiro; Naoki, Katsuhiko; Niimi, Tatsuya; Mimasu, Shinya; Sakagami, Hideki; Soejima, Kenzo; Betsuyaku, Tomoko.

In: Molecular Cancer Therapeutics, Vol. 17, No. 4, 01.04.2018, p. 740-750.

Research output: Contribution to journalArticle

Hirano, Toshiyuki ; Yasuda, Hiroyuki ; Hamamoto, Junko ; Nukaga, Shigenari ; Masuzawa, Keita ; Kawada, Ichiro ; Naoki, Katsuhiko ; Niimi, Tatsuya ; Mimasu, Shinya ; Sakagami, Hideki ; Soejima, Kenzo ; Betsuyaku, Tomoko. / Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non–small cell lung cancer. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 4. pp. 740-750.
@article{748c4b32f3cc44c88291029482811762,
title = "Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non–small cell lung cancer",
abstract = "Multiple epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) have been developed to effectively inhibit EGFR-derived signals in non–small cell lung cancer (NSCLC). In this study, we assessed the efficacy of EGFR-TKIs, including a novel third-generation inhibitor naquotinib (ASP8273), in clinically relevant EGFR mutations, including L858R, exon 19 deletion, L858R{\th}T790M, exon 19 deletion{\th}T790M with or without a C797S mutation, and several exon 20 insertion mutations. Using structural analyses, we also elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in EGFR exon 20 insertion mutations. The efficacy of naquotinib in cells with L858R, exon 19 deletion and exon 19 deletion{\th}T790M was comparable with that of osimertinib. Interestingly, naquotinib was more potent than osimertinib for L858R{\th}T790M. Additionally, naquotinib and osimertinib had comparable efficacy and a wide therapeutic window for cells with EGFR exon 20 insertions. Structural modeling partly elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in two EGFR exon 20 insertion mutants, A767_V769dupASV and Y764_V765insHH. In summary, we have characterized the efficacy of EGFR-TKIs for NSCLC using in vitro and structural analyses and suggested the mechanism of activation and resistance to EGFR-TKIs of EGFR exon 20 insertion mutations. Our findings should guide the selection of appropriate EGFR-TKIs for the treatment of NSCLC with EGFR mutations and help clarify the biology of EGFR exon 20 insertion mutations.",
author = "Toshiyuki Hirano and Hiroyuki Yasuda and Junko Hamamoto and Shigenari Nukaga and Keita Masuzawa and Ichiro Kawada and Katsuhiko Naoki and Tatsuya Niimi and Shinya Mimasu and Hideki Sakagami and Kenzo Soejima and Tomoko Betsuyaku",
year = "2018",
month = "4",
day = "1",
doi = "10.1158/1535-7163.MCT-17-1033",
language = "English",
volume = "17",
pages = "740--750",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non–small cell lung cancer

AU - Hirano, Toshiyuki

AU - Yasuda, Hiroyuki

AU - Hamamoto, Junko

AU - Nukaga, Shigenari

AU - Masuzawa, Keita

AU - Kawada, Ichiro

AU - Naoki, Katsuhiko

AU - Niimi, Tatsuya

AU - Mimasu, Shinya

AU - Sakagami, Hideki

AU - Soejima, Kenzo

AU - Betsuyaku, Tomoko

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Multiple epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) have been developed to effectively inhibit EGFR-derived signals in non–small cell lung cancer (NSCLC). In this study, we assessed the efficacy of EGFR-TKIs, including a novel third-generation inhibitor naquotinib (ASP8273), in clinically relevant EGFR mutations, including L858R, exon 19 deletion, L858RþT790M, exon 19 deletionþT790M with or without a C797S mutation, and several exon 20 insertion mutations. Using structural analyses, we also elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in EGFR exon 20 insertion mutations. The efficacy of naquotinib in cells with L858R, exon 19 deletion and exon 19 deletionþT790M was comparable with that of osimertinib. Interestingly, naquotinib was more potent than osimertinib for L858RþT790M. Additionally, naquotinib and osimertinib had comparable efficacy and a wide therapeutic window for cells with EGFR exon 20 insertions. Structural modeling partly elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in two EGFR exon 20 insertion mutants, A767_V769dupASV and Y764_V765insHH. In summary, we have characterized the efficacy of EGFR-TKIs for NSCLC using in vitro and structural analyses and suggested the mechanism of activation and resistance to EGFR-TKIs of EGFR exon 20 insertion mutations. Our findings should guide the selection of appropriate EGFR-TKIs for the treatment of NSCLC with EGFR mutations and help clarify the biology of EGFR exon 20 insertion mutations.

AB - Multiple epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) have been developed to effectively inhibit EGFR-derived signals in non–small cell lung cancer (NSCLC). In this study, we assessed the efficacy of EGFR-TKIs, including a novel third-generation inhibitor naquotinib (ASP8273), in clinically relevant EGFR mutations, including L858R, exon 19 deletion, L858RþT790M, exon 19 deletionþT790M with or without a C797S mutation, and several exon 20 insertion mutations. Using structural analyses, we also elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in EGFR exon 20 insertion mutations. The efficacy of naquotinib in cells with L858R, exon 19 deletion and exon 19 deletionþT790M was comparable with that of osimertinib. Interestingly, naquotinib was more potent than osimertinib for L858RþT790M. Additionally, naquotinib and osimertinib had comparable efficacy and a wide therapeutic window for cells with EGFR exon 20 insertions. Structural modeling partly elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in two EGFR exon 20 insertion mutants, A767_V769dupASV and Y764_V765insHH. In summary, we have characterized the efficacy of EGFR-TKIs for NSCLC using in vitro and structural analyses and suggested the mechanism of activation and resistance to EGFR-TKIs of EGFR exon 20 insertion mutations. Our findings should guide the selection of appropriate EGFR-TKIs for the treatment of NSCLC with EGFR mutations and help clarify the biology of EGFR exon 20 insertion mutations.

UR - http://www.scopus.com/inward/record.url?scp=85047924348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047924348&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-1033

DO - 10.1158/1535-7163.MCT-17-1033

M3 - Article

C2 - 29467275

AN - SCOPUS:85047924348

VL - 17

SP - 740

EP - 750

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -